Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Pfizer quarterly...

    Pfizer quarterly profit in line, touts pipeline of future products

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-01-31T09:05:29+05:30  |  Updated On 16 Aug 2021 3:21 PM IST

    On a call with analysts, new Chief Executive Albert Bourla said Pfizer had "the best pipeline in our history," and predicted that the company would return to sustained growth beginning in the middle of 2020.


    New Delhi: Pfizer Inc on Tuesday reported fourth-quarter profit and sales that edged past Wall Street estimates, helped by higher sales of breast cancer medicine Ibrance and pain drug Lyrica.


    The largest U.S. drugmaker also touted its pipeline of drugs in development and its shares rose more than 2 per cent after initially falling on a 2019 earnings forecast below Wall Street estimates. That continued a trend among major drugmakers as Johnson & Johnson and Bristol-Myers Squibb Co have also issued initial 2019 earnings forecasts below analysts' estimates.


    On a call with analysts, new Chief Executive Albert Bourla said Pfizer had "the best pipeline in our history," and predicted that the company would return to sustained growth beginning in the middle of 2020.


    Read Also: Pfizer says USFDA accepts regulatory submissions for review of tafamidis



    "Our job now is to stay the course," said Bourla, who took over as CEO to start the year.



    Pfizer forecast 2019 adjusted earnings of $2.82 to $2.92 per share, while analysts were estimating $3.04 per share, according to IBES data from Refinitiv. Its revenue forecast of $52 billion to $54 billion, which takes into account the impact of a stronger dollar and the loss of U.S. patent exclusivity on Lyrica around mid-year, also fell short of analysts' estimates of $54.25 billion.


    "The confidence in the pipeline and potential for accelerated growth beginning in 2020 is contributing to the positive share price reaction," Edward Jones analyst Ashtyn Evans said.


    Pfizer and partner Eli Lilly & Co also reported positive results from a late-stage trial of their experimental non-opioid arthritis treatment tanezumab, one of 15 potential billion-dollar drugs Pfizer says could win approval within five years. However, some analysts suggested that the new data may not alleviate safety concerns around the pain drug.


    Pfizer executives said they expected flat pricing for its drugs in the United States this year, but that it was not counting on price increases to drive growth.


    Bourla also said Lyrica would be its last top-selling product to go off patent until the second half of the decade.


    Pfizer's promising pipeline also includes potential blockbuster heart medicine tafamidis, as well as potentially lucrative vaccines and cancer drugs.


    Read Also: GSK, Pfizer to Merge Consumer Healthcare units

    In the fourth quarter, Ibrance sales rose 58 per cent to $1.13 billion, helped by growing demand in Europe.


    Excluding items, Pfizer earned 64 cents per share, exceeding analysts' average expectations by a penny. Revenue of $13.98 billion also edged past forecasts of $13.90 billion.

    Albert Bourlaarthritis treatmentbreast cancerBristol-Myers Squibbcancer drugsEli LillyIBESIbranceJohnson & Johnsonlucrative vaccinespain drug LyricaPfizerPfizer sharestafamidistanezumabtouts pipelineUnited States
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok